Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions
check our Global Reach for details
As a supplement company, Seeking Health cannot dispense medical advice or answer any medically related questions
The evidence is limited and methodologically weak
Your medications are now made especially for you Explore our resources designed specifically for prescribers to get the information and support you need at every step
Q7A: Good manufacturing practice guidance for active pharmaceutical ingredients
